✓ Translated by DotMD AI Clinical Council Source: Radiology • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #42937536 ↗

Phase III Randomized Trial: Automated Opportunistic Bone Mineral Density Assessment at Low-Dose CT Lung Cancer Screening: Incident Vertebral Fractures and Mortality (N = 18)

Original Paper Title: “Automated Opportunistic Bone Mineral Density Assessment at Low-Dose CT Lung Cancer Screening: Incident Vertebral Fractures and Mortality”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 18
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • NCT00047385 © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Bredella in this issue.
  • Study Design & Sample: Phase III Randomized Trial published in Radiology (N = 18 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Radiology (2026), this phase iii randomized trial evaluating 18 human participants investigated: Background Low-dose CT (LDCT) for lung cancer screening enables opportunistic volumetric bone mineral density (vBMD) assessment, but its prognostic value is unclear. Key clinical takeaway: NCT00047385 © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Bredella in this issue.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Radiology, 2026-10-15; N = 18; Rigor 82/100): NCT00047385 © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Bredella in this issue.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: mineral-ice-methol-pain-relief-menthol-10-5 → Rx: low-dose-naltrexone → Rx: oral-minoxidil → Condition: fractures → Condition: lung-cancer →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 42937536: Phase III Randomized Trial: Automated Opportunistic Bone Mineral Density Assessment at Low-Dose CT Lung Cancer Screening: Incident Vertebral Fractures and Mortality (N = 18)

3 of 3 Free Questions Remaining